Kiniksa Pharmaceuticals, Ltd. (KNSA)
- Previous Close
17.61 - Open
17.68 - Bid 17.84 x 100
- Ask 17.90 x 100
- Day's Range
17.45 - 18.05 - 52 Week Range
10.65 - 22.09 - Volume
331,616 - Avg. Volume
373,714 - Market Cap (intraday)
1.268B - Beta (5Y Monthly) 0.30
- PE Ratio (TTM)
137.54 - EPS (TTM)
0.13 - Earnings Date Jul 23, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.00
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
www.kiniksa.comRecent News: KNSA
Performance Overview: KNSA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KNSA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KNSA
Valuation Measures
Market Cap
1.27B
Enterprise Value
1.07B
Trailing P/E
137.54
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.27
Price/Book (mrq)
--
Enterprise Value/Revenue
3.56
Enterprise Value/EBITDA
-35.17
Financial Highlights
Profitability and Income Statement
Profit Margin
2.87%
Return on Assets (ttm)
-3.97%
Return on Equity (ttm)
2.11%
Revenue (ttm)
301.77M
Net Income Avi to Common (ttm)
8.65M
Diluted EPS (ttm)
0.13
Balance Sheet and Cash Flow
Total Cash (mrq)
213.55M
Total Debt/Equity (mrq)
2.81%
Levered Free Cash Flow (ttm)
26.97M